Anamorelin for Fat Loss
Oral ghrelin-receptor agonist developed for cancer cachexia; approved in Japan as Adlumiz.
Why Anamorelin for fat loss?
Anamorelin (ONO-7643) is an orally active selective ghrelin/GHSR-1a agonist. Approved in Japan (2021, Adlumiz, Ono Pharmaceutical) for cancer cachexia in NSCLC, gastric, pancreatic, and colorectal cancers. ROMANA-1/2 Phase 3 trials demonstrated lean-mass gains but failed handgrip-strength endpoints, leading to EMA refusal.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Anamorelin fits this goal because its category (Performance) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Improves appetite
Reference dosing by bodyweight
Anchored to the most-cited research dose (100000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 62333–84333 mcg |
| 60–75 kg / 132–165 lb | 76500–103500 mcg |
| 75–90 kg / 165–198 lb | 93500–126500 mcg |
| 90–105 kg / 198–231 lb | 110500–149500 mcg |
| >105 kg / >231 lb | 127500–172500 mcg |
Side effects to weigh against fat loss benefit
- Hyperglycemia
- Nausea
- Headache
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.